PUBLICATIONS

de la Cruz-Ojeda P, Parras-Martínez E, Rey-Pérez R, Muntané J. In silico analysis of lncRNA-miRNA-mRNA signatures related to sorafenib effectiveness in liver cancer cells. World J Gastroenterology 2025, Jan 21;31(3):95207.

de la Cruz-Ojeda P, Navarro-Villarán E, Fuertes-Agudo M, Mata A, López-Lluch G, Navas P, Cadenas S, Casado M, Muntané J. Peroxynitrite is involved in the mitochondrial dysfunction induced by Sorafenib in liver cancer cells. Free Radic Biol Med 2024 Dec 30:S0891-5849(24)01162-6.

Pieretti JC, Horne T, García-Villasante N, Seabra AB, Muntané J. Zinc-based nanoparticles, but not silicon-based nanoparticles, accumulate in mitochondria and promote cell death in liver cancer cells. Int J Nanomedicine 2024, Nov 23;19:12409-12420.

de la Cruz-Ojeda P, Schmid T, Boix L, Moreno M, Sapena V, Praena-Fernández JM, Castell FJ, Falcón-Pérez JM, Reig M, Brüne B, Gómez-Bravo MA, Giráldez A, Bruix J, Ferrer MT, Muntané J. miR-200c-3p, miR-222-5p, and miR-512-3p constitute a bomarker signature of Sorafenib effectiveness in advanced hepatocellular carcinoma. Cells 2022 Aug 28;11(17):2673.

de la Cruz-Ojeda P, Flores-Campos R, Navarro-Villarán E, Muntané J. The role of non-coding RNAs in autophagy during carcinogenesis. Front Cell Dev Biol 2022 Mar 2;10:799392.         

de la Cruz-Ojeda P, Flores-Campos R, Dios-Barbeito S, Navarro-Villarán E, Muntané J. Role of nitric oxide in gene expression regulation during cancer: epigenetic modifications and non-coding RNAs. Int J Mol Sci 2021;22(12):6264.

González R, Rodríguez-Hernández MA, Negrete M, Ranguelova K, Rossin A, Choya-Foces C, de la Cruz-Ojeda P, Miranda-Vizuete A, Martínez-Ruiz A, Rius-Pérez S, Sastre J, Bárcena JA, Hueber A-O, Padilla CA, Muntané J. Downregulation of Thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biol 2020;34:101528. 

Rodríguez-Hernández MA, de la Cruz-Ojeda P, Gallego P, Navarro-Villarán E, Staňková P, Del Campo JA, Kučera O, Elkalaf M, Maseko TE, Červinková Z, Muntané J. Dose-dependent regulation of mitochondrial function and cell death pathway by Sorafenib in liver cancer cells. Biochem Pharmacol 2020; Jun 1;176:113902. 

Rodríguez-Hernández MA, Chapresto-Garzón R, Cadenas M, Navarro-Villarán E, Negrete M, Gómez-Bravo MA, Victor VM, Padillo FJ, Muntané J. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death and Disease 2020 May 7;11(5):339. 

Rodríguez-Hernández MA, de la Cruz-Ojeda P, López-Grueso MJ, Navarro-Villarán E, Requejo-Aguilar R, Castejón-Vega B, Negrete M, Gallego P, Vega-Ochoa A, Victor VM, Cordero MD, Del Campo JA, Bárcena JA, Padilla CA, Muntané J. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020 May 23;36:101510. 

Navarro-Villarán E, de la Cruz-Ojeda P, Contreras L, González R, Negrete M, Rodríguez-Hernández MA, Marín-Gómez LM, Álamo-Martínez JM, Gómez-Bravo MA, de la Cruz J, Padillo J, Muntané J. Molecular pathways leading to induction of cell death and anti-proliferative properties by Tacrolimus and mTOR inhibitors in liver cancer cells. Cell Physiol Biochem. 2020 May 6;54(3):457-473.

Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Hepatology 2019 Aug;70(2):547-562 .

Rodríguez-Hernández MA, González R, De la Rosa AJ, Gallego P, Ordoñez R, Navarro-Villarán E, Contreras L, Rodríguez-Arribas M, González-Gallego J, Álamo-Martínez JM, Marín-Gómez LM, Del Campo JA, Quiles JL, Fuentes JM, de la Cruz J, Mauriz JL, Padillo FJ, Muntané J. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. J Cell Physiol 2018 Jan;234(1):692-708. 

González R, Molina-Ruiz FJ, Ruiz JAB, Padilla CA, Muntané J.  Regulation of cell survival, apoptosis and epithelial to mesenchymal transition by nitric oxide-dependent post-translational modifications. Antioxid. Redox Signal. 2018 Nov 1;29(13):1312-1332.            .

Gonzalez R, De la Rosa AJ, Rufini A, Rodríguez-Hernández A, Navarro-Villarán E, Marchal T, Pereira S, De la Mata M, Müller-Schilling M, Pascasio-Acevedo JM, Ferrer-Ríos MT, Gómez-Bravo MA, Padillo FJ, Muntané J. Role of TA and ΔN p63 and p73 isoforms on the regulation of cell death and tumor recurrence in patients with hepatocellular carcinoma submitted to liver transplantation. Plos One 2017 Mar 28;12(3):e0174326.

Navarro-Villarán E, Tinoco J, Jiménez G, Pereira S, Wang J, Aliseda S, Rodríguez-Hernández MA, González R, Marín-Gómez LM, Gómez-Bravo MA, Padillo FJ, Álamo-Martínez JM, Muntané J. Differential antitumoral properties and renal-associated tissue damage induced by Tacrolimus and mamalian target of rapamycin inhibitors in hepatocarcinoma: in vitro and in vivo studies. PLoS One 2016 Agosto 12;11(8):e0160979.

Urtasun R, Elizalde M, Azkona M, Latasa MU, García-Irigoyen O, Uriarte I, Fernández-Barrena MG, Vicent S, Alonso MM, Muntané J, Prieto J, Ávila MA, Berasain C. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic mir-17-92 cluster expression. Oncogene 2016 Septiembre 8;35(36):4719-4729.

Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, Nogales-Muñoz A, Gila-Bohórquez A, Pacheco D, Torres-Nieto MA, Serrano-Díaz-Canedo J, Suárez-Artacho G, Bernal-Bellido C, Marín-Gómez LM, Barcena JA, Gómez-Bravo MA, Padilla CA, Padillo FJ, Muntané J. Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biol. 2015 Diciembre;6:174-182.

Madejón A, Sheldon J, Francisco-Recuero I, Perales C, Domínguez-Beato M, Lasa M, Sánchez-Perez I, Muntané J, Domingo E, García-Samaniego J, Sánchez-Pacheco A.  Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. J Hepatol. 2015 Agosto;63(2):312-319.

Castaño D, Larequi E, Belza I, Astudillo AM, Martínez-Ansó E, Balsinde J, Argemi JM, Aragon T, Moreno-Aliaga MJ, Muntane J, Prieto J, Bustos M. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving. AMPK activation. J Hepatol 2014 Mayo;60(5):1017-1025.

González R, Ferrín G, Aguilar-melero P, Ranchal I, Linares CI, Bello RI, De la Mata M, Gogvadze V, Bárcena JA, Álamo JM, Orrenius S, Padillo J, Zhivotovsky B, Muntané J. Targeting hepatoma using NO donor strategies. Antioxid. Redox Signal. 2013 Febrero 10;18(5):491-506.

Aguilar-Melero P, Ferrín G, Muntané J. Effects of nitric oxide synthase-3 overepxresion on post-translational modifications and cell survival in HepG2. Journal of Proteomics 2012 Enero 4;75(3): 740-755.